Angiosarcoma: State of the art and perspectives

Critical Reviews in Oncology/Hematology

Volumn 80, Issue 2, 2011, Pages 257-263

  Penel, Nicolas ^a,b,c   Marréaud, Sandrine ^a,b   Robin, Yves Marie ^c   Hohenberger, Peter ^a,b  

^a EORTC Headquarters ^*  (Belgium)

^b EORTC Soft Tissue and Bone Sarcoma Group   (Belgium)

^c CENTRE OSCAR LAMBRET   (France)

Author keywords

Angiogenesis; Angiosarcoma; Prognostic factors; Weekly paclitaxel

Indexed keywords

DOXORUBICIN; IFOSFAMIDE; IMATINIB; PACLITAXEL; SORAFENIB;

ANGIOSARCOMA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL FEATURE; DRUG DOSE REDUCTION; DRUG TARGETING; FACE CANCER; HISTOPATHOLOGY; HUMAN; LYMPHEDEMA; LYMPHOMA; MASTECTOMY; METASTASIS POTENTIAL; MOLECULAR THERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIMARY TUMOR; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIATION INDUCED NEOPLASM; REVIEW; SCALP TUMOR; SOFT TISSUE SARCOMA; STEWART TREVES SYNDROME; SURVIVAL TIME;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRIDGED COMPOUNDS; DOXORUBICIN; HEMANGIOSARCOMA; HUMANS; TAXOIDS;

EID: 80053934746     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2010.10.007     Document Type: Review

References (64)

1. Torosian M.H., Friedrich C., Godblod J., Hadju S.I., Brennan M. Soft-tissue sarcoma: initial characteristics and prognostic factors in patients with or without metastatic disease. Sem Surg Oncol 1988, 4:13-19.
2. Coindre J.M., Terrier P., Guillou L., et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas. A study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer 2001, 91:1914-1926.
3. Penel N., Grosjean J., Robin Y.M., Vanseymortier L., Clisant S., Adenis A. Frequency of certain established risk factors in soft tissue sarcomas in adult: a prospective descriptive study of 658 cases. Sarcoma 2008, 2008:459386.
4. Fury M.G., Antonescu C.R., Van Zee K.J., Brennan M.E., Maki R.G. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with sugery and chemotherapy. Cancer J 2005, 11:241-247.
5. Fayette J., Martin E., Piperno-Neumann S., et al. Angiosarcomas, a herogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. Ann Oncol 2007, 18:2030-2036.
6. Meis-Kindblom J., Kindblom L.G. Angiosarcoma of soft tissue: a study of 80 cases. Am J Surg Pathol 1998, 22:683-697.
7. Thomas L.B., Popper H. Pathology of angiosarcomas of the liver among vinyl chloride-polychloride workers. Ann NY Acad Sci 1975, 246:268-285.
8. El-Ghissassi F., Boivin S., LeFrancois L., Barbin A., Marion M.J. Glutathione transferase mu1-1 (GSTM1) genotype in individuals exposed to vinyl chloride: a relation to " vinyl chloride disease" and liver angiosarcoma. Clin Chem 1995, 41:1922-1924.
9. Viola P.L., Bigotti A., Caputo A. Oncogenic response to rat skin lungs and bones to vinyl chloride. Cancer Res 1971, 31:516-522.
10. Sordillo E.M., Chapman R., Hadju S.I., Magill G.B., Golbey R.B. Lymphangiosarcoma. Cancer 1981, 48:1674-1679.
11. Woodward A.H., Ivins J.C., Soule E.H. Lymphangiosarcoma arising in chronic lympedematous extremities. Cancer 1972, 30:562-572.
12. Salas S., Stock N., Stoeckle E., Kind M., Bui B., Coindre J.M. Chronic lymphedema due to morbid obesity: an exceptional cause of abdominal wall angiosarcoma. Virchow Arch 2008, 453:217-219.
13. Virtanen, Pukkala E., Auvinen A. Angiosarcoma after radiotherapy: a cohort study of 332,163 Finnish cancer patients. Br J Cancer 2007, 97:15-117.
14. Naka N., Oshawa M., Tomita Y., et al. Prognostic factors in angiosarcoma: a multivariate analysis of 55 cases. J Surg Oncol 1996, 61:170-176.
15. Maddox J.C., Evans H.L. Angiosarcoma of skin and soft tissue. A study of 44 cases. Cancer 1981, 48:1907-1921.
16. Gengler C., Coindre J.M., Leroux A., et al. Vascular proliferation of the skin after radiation therapy for breast cancer: clinicopathologic analysis of a series in favour of a benign process: a study from the French Sarcoma Group. Cancer 2007, 109:1584-1598.
17. Robin Y.M., Guillou L., Michels J.J., Coindre J.M. Angiosarcomas are negative for Humanvirus 8 immunostaining. Am J Clin Pathol 2004, 121:330-334.
18. Zietz C., Rössle M., Haas C., et al. MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. Am J Pathol 1998, 153:1425-1433.
19. Przygozki R.M., Finkelstein S.D., Keohavong P., et al. Sporadic and thorotrast-induced angiosarcoma of the liver manifest frequent and multiple point mutations in K-ras 2. Lab Invest 1997, 76:153-159.
20. Manner J., Radlwimmer B., Hohenberger P., et al. MYC level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphoedema. Am J Pathol 2010, 176:34-39.
21. Abraham J.A., Hornicek F.J., Kaufman A.M., et al. Treatment and outcome of 82 patients with angiosarcoma. Ann Surg Oncol 2007, 14:1953-1967.
22. Mark R.J., Poen J.C., Tran L.M., Fu T.S., Juillard G.F. Angiosarcoma. A report of 67 patients and a review of the literature. Cancer 1996, 77:2400-2406.
23. Fong Y., Coit, Wodruff J., Brennan M.F. Lymph node metastasis from soft tissue sarcoma in adults: analysis data from a prospective database of 1772 sarcoma patients. Ann Surg 1993, 218:72-77.
24. Behranwala K.A., A'Hern R., Omar A.M., Thomas J.M. Prognosis of lymph node metastasis in soft tissue sarcoma. Ann Surg Oncol 2004, 11:714-719.
25. Riad S., Griffin Am, Liberman B., et al. Lymph node metastasis in soft tissue sarcoma in an extremity. Clin Orthop Relat Res 2004, 426:129-134.
26. Vorburger S.A., Xing Y., Hunt K.K., et al. Angiosarcoma of the breast. Cancer 2005, 104:2682-2688.
27. Morgan M.B., Swann M., Somach S., Eng W., Smoller B. Cutaneous angiosarcoma: a case series with prognostic correlation. J Am Acad Dermatol 2004, 50:867-874.
28. Wang X.Y., Jakowski J., Tawfik O.W., Thomas P.A., Fan F. Angiosarcoma of the breast: a clinicopathologic analysis of cases from the last 10 years. Ann Diagn Pathol 2009, 13:147-150.
29. Zelek L., Llombart-Cussac A., Terrier P., et al. Prognostic factor in primary breast sarcomas: a series of patients with long-term follow-up. J Clin Oncol 2003, 21:2583-2588.
30. Pawlik T.M., Paulino A.F., McGinn C.J., et al. Cutaneous angiosarcoma of the scalp: a multidisciplinary approach. Cancer 2003, 98:1716-1726.
31. Holden C.A., Spittle M.F., Jones E.W. Angiosarcoma of the face and scalp: prognosis and treatment. Cancer 1987, 59:1046-1057.
32. Harvey E.B., Brinton L.A. Second cancer following cancer of the breast in Connecticut, 1935-1982. Natl Cancer Inst Monogr 1985, 68:99-112.
33. Casali P.G., Jost L., Sleijfer S., Verweij J., Blay J.Y. On behalf of the ESMO Guidelines Working Group. Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008, 19:ii89-ii93.
34. Vogt T., Hafner C., Bross K., et al. Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofsfamide with advanced malignant vascular tumors. Cancer 2003, 98:2251-2256.
35. Fidias P., Demetri G., Harmon D. Navelbine shows activity in previously treated sarcoma patients: Phase II results from MGH/Dana-Farber/Partner's Cancer Care Study. Proc Am Soc Clin Oncol 1998, 17:1977.
36. Skubitz K., Haddad P.A. Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer 2005, 104:361-366.
37. Raina V., Sengar M., Shukla N.K., et al. Complete response from thalidomide in angiosarcoma after treatment of breast cancer. J Clin Oncol 2007, 25:900-901.
38. Kopp H.G., Kanz L., Hartmann J.T. Complete remission of relapsing high-grade angiosarcoma with single-agent metronomic trofosfamide. Anticancer Drugs 2006, 17:997-998.
39. Fata F., O'Reilly E., Ilson D., et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 1999, 86:2034-2037.
40. Schlemmer M., Reichardt P., Verweij J., et al. Paclitaxel in patients with adanced angiosarcomas of soft tissue: a retrospective study of the EORTC Soft Tissue and Boenne Sarcoma Group. Eur J Cancer 2008, 44:2433-2436.
41. Nagano T., Yamada Y., Ikeda T., Kanki H., Kamo T., Nishigori C. Docetaxel: a therapeutic option in the treatment of cutaneous angiosarcomas: report of 9 patients. Cancer 2007, 110:648-651.
42. Mano M.S., Fraser G., Kerr J., et al. Radiation-induced angiosarcoma of the breast shows major response to docetaxel after failure of anthracycline-based chemotherapy. Breast 2004, 15:117-118.
43. Penel N., Bui B.N., Bay J.O., et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the AngioTax study. J Clin Oncol 2008, 26:5269-5274.
44. Verweij J., Lee S.M., Ruka W., et al. Randomized phase II study of docetaxel versus doxorubicin in first-line and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 2000, 18:2081-2086.
45. Köstler W.J., Brodowicz T., Attems Y., et al. Docetaxel as rescue medication in anthracyclines- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial. Ann Oncol 2001, 12:1281-1288.
46. Pivot X., Chevreau C., Cupissol D., et al. Phase II trial of paclitaxel-epirubicin in patients wit recurrent soft tissue sarcoma. Am J Clin Oncol 2002, 25:661-664.
47. Maki R.G., D'Adamo D.R., Keohan M.L., et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009, 27:3133-3140.
48. Chugh R., Wathen J.K., Maki R.G., et al. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a Bayesian hierarchical statistical model. J Clin Oncol 2009, 27:3148-3153.
49. Agulnik M., Okuno S.H., Von Mehren M., et al. An open-label multicenter phase II study of bevacizumab for the treatment of angiosarcoma. J Clin Oncol 2009, 27:15s. [Suppl; Abstr 10522].
50. Vergier B., Carry L., Bonnet F., Robert J., de Mascarel A., Coindre J.M. Expression of MDR1/P Glycoprotein in human sarcomas. Br J Cancer 1993, 68:1221-1226.
51. Dumontet C., Duran G.E., Steger K.A., Beketic-Oreskovic L., Sikic B.I. Resistance mechanism in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). Cancer Res 1996, 56:1091-1097.
52. Houghton J.A., Houghton P.J., Hazelton B.J., Douglass E.C. In situ selection of a human rhabdomyosarcoma resistant to vincristine with altered beta-tubulin. Cancer Res 1985, 45:2706-2712.
53. Brown L., Tognazzi K., Dvorak H.F., Harrist T.J. Strong expression of kinase insert domain-containing receptor, a vascular permeability factor/vascular endothelial growth factor receptor in AIDS-associated Kaposi and cutaneous angiosarcoma. Am J Pathol 1996, 148:1065-1074.
54. Amo Y., Masuzawa M., Hamada Y., Katsouka K. Expression of vascular endothelial growth factor in a human hemangiosarcoma cell line (ISO-HAS). Arch Dermatol Res 2001, 293:296-301.
55. Naito S., Shimizu K., Nakashima M., et al. Overexpression of Ets-1 transcription factor in angiosarcoma of the skin. Pathol Res Pract 2000, 196:103-109.
56. Moyer C., Allen D., Basabe A., Maronpot R.R., Nyska A. Analysis of vascular endothelial growth factor (VEGF) and recptor subtype (KDR/flk-1) in the liver of rat exposed to riddeline: a potential role in the developpment of hemangiosarcoma. Exp Toxicol Pathol 2004, 55:455-465.
57. Itakura E., Yamaoto H., Oda Y., Tsuneyoshi M. Detection and characterization of vascular endothelia growth factors and their receptors in a series of angiosarcoma. J Surg Oncol 2008, 97:74-81.
58. LaMontagne K.R., Moses M.A., Wiederschain D., et al. Inhibition of MAP kinases causes morphological reversion and dissociation between soft agar growth and in vivo tumorigenesis in angiosarcoma cells. Am J Pathol 2000, 157:1937-1945.
59. Rathmell W.K., Acs G., Simon M.C., Vaughn D.J. HIF transcription factor expression and induction of hypoxic response genes in a retroperitoneal angiosarcoma. Anticancer Res 2004, 24:167-169.
60. Arbiser J.L., Larsson H., Claesson-Welsh L., et al. Overexpression of VEGF 121 in immortalized endothelial cell causes conversion to slowly growing angiosarcoma and high level expression of the VEGF receptors VEGF-R1 and VEGF-R2 in vivo. Am J Pathol 2000, 156:1469-1476.
61. Antonescu C.R., Yoshida A., Guo T., et al. KDR activating mutations in human aniosarcomas are sensitive to specific kinase inhibition. Cancer Res 2009, 69:71-79.
62. Krump-Konvalinkova V., Bittinger F., Olert J., Braüninger W., Brunner J., Kirkpatrick C.J. Establishment and characterization of an angiosarcoma derived cell line, AS-H. Endothelium 2003, 10:319-328.
63. Lahat G., Dhuka A.R., Hallevi H., et al. Angiosarcoma: clinical and molecular insights. Ann Surg 2010, 251:1098-1106.
64. Singer S., Corson J., Gonin R., Labow B., Eberlein T.J. Prognostic factors predictive of survival and local recurrence for extremity soft tissue sarcoma. Ann Surg 1994, 219:165-173.